Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Real world data for CD19 CAR-T in lymphoma patients in England

Claire Roddie • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma CAR-T

Claire Roddie, MD, PhD, University College London, London, United Kingdom, discusses real world data for relapsed/refractory high-grade lymphoma patients treated with CD19 CAR-T in England. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Claire Roddie

CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more 17:12
CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more
Bijal Shah et al. • 11 Apr 2025
Insights into the UCL CAR T program 1:28
Insights into the UCL CAR T program
Claire Roddie • 3 Jun 2023
Updates in ALL
Bijal Shah et al. • 12 May 2023
Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejection 3:38
Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejection
Claire Roddie • 3 Jun 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals